Pin Wang, PhD

Professor

Image of Pin Wang, PhD
Is this your profile? Click to edit

Overview

The Wang laboratory focuses on an emerging field of “immunobioengineering” with the aim of employing engineering tools and principles to quantitatively understand the immune system in health and disease and to develop novel molecular and cellular immunotherapies by precisely modulating disease-specific immune responses. The ongoing research research projects include: 1) exploring various strategies to engineer virus-derived vector systems for dendritic cell-targeted vaccine delivery and oncolytic virus-based immunotherapy; 2) designing and optimizing cellular immunotherapy that is based on molecular engineering of chimeric antigen receptors (CARs); 3) exploring immune cells as drug carriers for targeted delivery of immunomodulatory drugs to enhance cancer immunotherapy; 4) exploring systems biology tools for modeling and understanding details of signaling pathways mediated by designer molecules such as chimeric antigen receptors to activate T cells; 5) developing engineering methods to improve adeno-associated virus (AAV)-based gene delivery. In this research laboratory, bioengineers collaborate with chemists, immunologists, computer scientists, and system biologists to directly address problems in translational immunology and develop and optimize innovative approaches to improve lives of patients suffering from cancer and infectious diseases.

Research Funding

  • In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.
    NIH · R01EB017206 · Sep 1, 2013 – Aug 31, 2020 · Role: Co-Principal Investigator
  • SUPR Peptides to Inhibit Undruggable Cancer Target (PQ18)
    NIH · R01CA170820 · Sep 17, 2012 – Jun 30, 2017 · Role: Co-Principal Investigator
  • Targeting lentiviruses to infect chosen cells
    NIH · R01AI068978 · Feb 1, 2006 – Jan 31, 2012 · Role: Principal Investigator

Research Keywords

  • Cancer Immunotherapy
  • Immunoengineering
  • T Cell Engineering
  • Chimeric Antigen Receptor
  • Cancer Vaccine
  • Gene Therapy
  • Immuno-Oncology

Publications

  • Antibody-mimetic ligand selected by mRNA display targets DC-SIGN for dendritic cell-directed antigen delivery. ACS Chem Biol. 2013 May 17; 8(5):967-77.. View in PubMed
  • Genome mining of a prenylated and immunosuppressive polyketide from pathogenic fungi. Org Lett. 2013 Feb 15; 15(4):780-3.. View in PubMed
  • Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs. Biomaterials. 2013 Apr; 34(12):3098-109.. View in PubMed
  • Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice. PLoS One. 2012; 7(11):e48866.. View in PubMed
  • Site-specific modification of adeno-associated viruses via a genetically engineered aldehyde tag. Small. 2013 Feb 11; 9(3):421-9.. View in PubMed
  • Discovery and characterization of a group of fungal polycyclic polyketide prenyltransferases. J Am Chem Soc. 2012 Jun 06; 134(22):9428-37.. View in PubMed
  • Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells. Gene Ther. 2013 Mar; 20(3):308-17.. View in PubMed
  • PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines. Mol Ther. 2012 Sep; 20(9):1800-1809.. View in PubMed
  • A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses. Vaccine. 2012 Mar 28; 30(15):2570-81.. View in PubMed
  • Construction of stable producer cells to make high-titer lentiviral vectors for dendritic cell-based vaccination. Biotechnol Bioeng. 2012 Jun; 109(6):1551-60.. View in PubMed